Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEHP/PVC

This article was originally published in The Gray Sheet

Executive Summary

FDA expects to issue a guidance on labeling for devices containing di(2-ethylhexyl)phthalate (DEHP) "in the very near future," according to an April 5 letter from the agency to Health Care Without Harm denying the group's Oct. 5, 2001 petition for reconsideration. In September 2001, the agency denied HCWH's initial citizen petition requesting that all polyvinyl chloride medical devices be required to bear warning labels and that FDA encourage the development of alternatives to PVC (1"The Gray Sheet" Sept. 10, 2001, p. 18). In the April letter, FDA maintains that HCWH failed to satisfy the criteria required for the agency to grant a petition for reconsideration...

You may also be interested in...



DEHP Study Prompts FDA To Consider Safety/Availability Of PVC Alternatives

FDA will examine the safety and availability of alternatives to devices containing the plasticizer di-2-ethylhexyl-phthalate (DEHP) before considering a risk management strategy.

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.

 

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.
UsernamePublicRestriction

Register

MT016435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel